According to a report by Intel Market Research, the global Afamelanotide Market was valued at USD 136.27 million in 2024 and is projected to reach USD 258.01 million by 2032, expanding at a CAGR of 9.1% during the forecast period (2025–2032). The market is witnessing steady growth due to the increasing prevalence of rare phototoxic disorders such as erythropoietic protoporphyria (EPP),...

The growing prevalence of bile duct cancer and the increasing demand for advanced oncology treatments are significantly contributing to the expansion of the global therapeutics market. Rising investments in cancer research, improved diagnostic technologies, and the introduction of targeted therapies are transforming the treatment landscape for cholangiocarcinoma, commonly known as bile duct...

The global Netherton syndrome market is witnessing remarkable growth due to increasing awareness regarding rare genetic skin disorders, rising investments in orphan drug development, and expanding research activities focused on innovative dermatological therapies. Netherton syndrome is a rare autosomal recessive genetic disorder characterized by chronic skin inflammation, hair shaft...

The global rare neurological disease treatment market is witnessing substantial growth due to increasing awareness regarding rare neurological disorders, rising investments in orphan drug development, and rapid advancements in biotechnology and precision medicine. Rare neurological diseases are complex disorders that affect the brain, spinal cord, nerves, and muscles, often leading to severe...

Global economic fluctuations and shifting trade policies are casting a long shadow over the pharmaceutical supply chain. Companies are increasingly "friend-shoring" or "near-shoring" their outsourced services to mitigate the risks of geopolitical instability and logistics disruptions. This has led to a resurgence in service hubs within North America and Europe, even as Asia-Pacific remains a...